following a full submission:
ozanimod (Zeposia®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
In a randomised, double-blind, phase III study in patients with moderately to severely active UC, clinical remission was achieved by a significantly greater proportion of patients who received ozanimod compared with placebo after induction and maintenance treatment.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the economic results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice955KB (PDF)
Medicine details
- Medicine name:
- ozanimod (Zeposia)
- SMC ID:
- SMC2478
- Indication:
Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy (CvT) or a biologic agent.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 October 2022